15 September 2025
Biotech companies are increasingly turning to specialized contract research organizations (CROs) to handle their clinical trials, especially for complex and innovative therapies like allogeneic CAR-T. While large, traditional CROs have long been the industry standard, their one-size-fits-all model often creates significant risks for the unique needs of biotech firms. The high-stakes nature of groundbreaking research...